Myelodysplastic syndrome (MDS) and myeloproliferative neoplasms are chronic bone marrow diseases that affect blood-forming stem cells. Seattle Cancer Care Alliance (SCCA) is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation.
The doctors at SCCA and its founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine, are world leaders in research working to better understand and more effectively treat these diseases.
SCCA offers the full spectrum of standard MDS therapies, such as the growth factor erythropoietin, which may increase red blood cells, and the drugs azacitidine (Vidaza) and decitabine (Dacogen).
For people with advanced MDS, our doctors may recommend chemotherapy like that used for acute myelogenous leukemia. In addition, we offer treatments that are not yet commercially available but show promise in clinical studies, like the new formulation of azacitidine, which is taken as a pill.
We also offer bone marrow transplantation (also called stem cell transplantation or hematopoietic cell transplantation)—the only treatment option with the potential to cure MDS. We are actively investigating novel transplant approaches to improve overall survival for people with MDS.